Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Documenti analoghi

• A Clinical Practice Perspective on the Evaluation of OATP1B1‐associated Drug Interactions
  di: Céline K. Stäuble, et al.
  Pubblicazione: (2024)
• Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study
  di: Leila Potzel, et al.
  Pubblicazione: (2026)
• Pregnenolone Sulfate Permeation at the Blood–Brain Barrier is Independent of OATP2B1—In Vivo and In Vitro Insights
  di: Valerio Taggi, et al.
  Pubblicazione: (2025)
• Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story
  di: Yuki Ujihira, et al.
  Pubblicazione: (2025)
• A face‐to‐face comparison of the BBB cell models hCMEC / D3 and hBMEC for their applicability to adenoviral expression of transporters
  di: Valerio Taggi, et al.
  Pubblicazione: (2024)